Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $10.00 Price Target at HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target reduced by equities researchers at HC Wainwright from $20.00 to $10.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 416.80% from the stock’s previous close.

ZNTL has been the topic of a number of other reports. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Guggenheim decreased their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, UBS Group dropped their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.58.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock traded down $0.47 on Wednesday, hitting $1.94. 10,291,794 shares of the company’s stock were exchanged, compared to its average volume of 2,707,931. Zentalis Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $18.07. The stock has a market cap of $137.89 million, a P/E ratio of -0.77 and a beta of 1.86. The firm has a 50 day moving average price of $3.02 and a two-hundred day moving average price of $3.31.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. Sell-side analysts expect that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals in the third quarter worth approximately $37,000. Aigen Investment Management LP acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth about $41,000. Capstone Investment Advisors LLC acquired a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at $48,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.